News – Page 2 – Alligator Bioscience

2018-09-28

Regulatory

New preclinical data support good tolerability properties for the 4-1BB antibody ATOR-1017

Lund, Sweden, September 28, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmac ...

2018-08-30

Lund, Sweden, August 30 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals ...

2018-07-19

Regulatory

Lund, Sweden, July 19, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...

2018-07-12

Regulatory

Positive data for our preclinical projects Significant events April-June• The ADC-1013 clinical phase I study performed by Janssen is ongoin ...

2018-06-25

To read the whole magazine, open the PDF-file at the bottom of this email.

2018-06-21

– Further preclinical findings support a best-in-class profile – Oral presentation at World Preclinical Congress, ...

2018-05-29

Meet the future of antibody-based immuno-oncology drugs Lund, Sweden, May 29, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a ...

2018-05-16

Meet the future of antibody-based immuno-oncology drugs Lund, Sweden, May 16, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a ...

2018-05-08

ALG.APV-527 is Designed to Strategically Target and Engage the Immune System for the Potential Treatment of Multiple Solid Tumor Indications ...